Skip to main content

Advertisement

SpringerLink
Log in

2-[18F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

Fludarabine has proven to be of considerable efficacy in the treatment of low-grade lymphomas. We have developed the labeling of this drug with fluorine-18 and evaluated 2-[18F]fludarabine as a novel positron emission tomography (PET) probe for in vivo imaging.

Procedures

Preclinical studies were conducted with 2-[18F]fludarabine, in parallel with 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG), in Swiss CD-1 and CB17 severely combined immunodeficient (SCID) mice, both as tumor-free control groups, and SCID mice bearing RL lymphomas.

Results

In Swiss mice, micro-PET studies with 2-[18F]fludarabine showed a distribution restricted to the organs of excretion and the spleen, the latter being less evident in SCID animals. In lymphoma-bearing SCID mice, 2-[18F]fludarabine demonstrated a rapid tumor uptake over the first 20 min which subsequently plateaued and provided an improved contrast than that of [18F]FDG.

Conclusion

This radiotracer merits further evaluation to establish its clinical usefulness to image low-grade lymphoma in humans in future clinical investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Seam P, Juweid ME, Cheson BD (2007) The role of FDG-PET scans in patients with lymphoma. Blood 110:3507–3516

    Article  CAS  PubMed  Google Scholar 

  2. Schöder H, Moskowitz C (2008) PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin N Am 46:225–42

    Article  PubMed  Google Scholar 

  3. Elstrom R, Guan L, Baker G et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875–3876

    Article  CAS  PubMed  Google Scholar 

  4. Schöder H, Noy A, Gönen M et al (2005) Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphomas. J Clin Oncol 23:4643–4651

    Article  PubMed  Google Scholar 

  5. Tsukamoto N, Kojima M, Hasegawa M et al (2007) The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma. Relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652–659

    Article  PubMed  Google Scholar 

  6. Hoffmann M, Kletter K, Becherer A et al (2003) 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64:336–340

    Article  CAS  PubMed  Google Scholar 

  7. Gill S, Wolf M, Prince HM et al (2008) [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 8:159–165

    Article  PubMed  Google Scholar 

  8. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G et al (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66:11055–11061

    Article  CAS  PubMed  Google Scholar 

  9. Robak T, Korycka A, Lech-Maranda E, Robak P (2009) Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 23(14):1183–1226

    Article  Google Scholar 

  10. Keating MJ, O’Brien S, McLaughlin P et al (1996) Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 38:83–91

    Google Scholar 

  11. Leporrier M (2004) Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Hematol J 5:10–19

    Article  Google Scholar 

  12. Henrich S, Mactier S, Best G et al (2011) Fludarabine nucleoside modulates nuclear “survival and death” proteins in resistant chronic lymphocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids 30:1181–1189

    Article  CAS  PubMed  Google Scholar 

  13. Barrueco JR, Jacobsen DM, Chang CH et al (1987) Proposed mechanism of therapeutic selectivity for 9-β-d-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res 47:700–706

    CAS  PubMed  Google Scholar 

  14. Grégoire V, Van NT, Stephens LC et al (1994) The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 54:6201–6209

    PubMed  Google Scholar 

  15. Plunkett W, Gandhi V, Huang P et al (1993) Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2–12

    CAS  PubMed  Google Scholar 

  16. Gandhi V, Plunkett W (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93–103

    Article  CAS  PubMed  Google Scholar 

  17. Danhauser L, Plunkett W, Keating M, Cabanillas F (1986) 9-beta-d-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18:145–152

    Article  CAS  PubMed  Google Scholar 

  18. Marchand P, Lorilleux C, Gilbert G et al (2010) Efficient radiosynthesis of 2-[18F]fluoroadenosine: a new route to 2-[18F]fluoropurine nucleosides. ACS Med Chem Lett 1:240–243

    Article  CAS  Google Scholar 

  19. Guillouet S, Patin D, Tirel O et al. (2013) Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma. Mol Imaging Biol (in press)

  20. Dalle S, Dupire S, Brunet-Manquat S et al (2009) In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 15:851–857

    Article  CAS  PubMed  Google Scholar 

  21. Bao Q, Newport D, Chen M et al (2009) Performance evaluation of the Inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 50:401–408

    Article  PubMed Central  PubMed  Google Scholar 

  22. Müller-Hermelink HK, Montserrat E, Catovsky D et al (2008) Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 180–182

    Google Scholar 

  23. Kirschner AS, Ice RD, Beierwaltes WH (1975) Radiation dosimetry of 131I-19-iodocholesterol: the pitfalls of using tissue concentration data, the author’s reply. J Nucl Med 16(3):248–249

    CAS  Google Scholar 

  24. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027

    PubMed  Google Scholar 

  25. Friedberg JW (2010) PET positive, PET negative, or PET peeve? Blood 115:752–753

    Article  CAS  PubMed  Google Scholar 

  26. Karam M, Novak L, Cyriac J et al (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107:175–183

    Article  PubMed  Google Scholar 

  27. Keating MJ, O’Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079–4088

    Article  CAS  PubMed  Google Scholar 

  28. Byrd JC, Rai K, Peterson BL et al (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49–53

    Article  CAS  PubMed  Google Scholar 

  29. Eichhorst BF, Busch R, Hopfinger G et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885–891

    Article  CAS  PubMed  Google Scholar 

  30. Catovsky D, Richards S, Matutes E et al (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370:230–239

    Article  CAS  PubMed  Google Scholar 

  31. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174

    Article  CAS  PubMed  Google Scholar 

  32. Solal-Céligny P, Brice P, Brousse N et al (1996) Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 14(2):514–519

    PubMed  Google Scholar 

  33. Ladel CH, Bamberger U, Püschner H (1991) Histological and cytofluorometric investigations of immunodeficient CB17 SCID/SCID mice. Verh Dtsch Ges Pathol 75:108–113

    CAS  PubMed  Google Scholar 

  34. Deloar HM, Fujiwara T, Shidahara M et al (1998) Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 25:565–57

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the staff members of the team for their service and support. This work has been in part supported by a grant from the French National Agency for Research called “Investissements d’Avenir” no. ANR-11-LABEX-0018-01, the Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), and the region Basse Normandie.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. CEA, DSV/I2BM, LDM-TEP Group, GIP Cyceron, Bd Henri Becquerel, , BP 5229, , 14074, Caen Cedex, France

    Martine Dhilly, Stéphane Guillouet, Delphine patin, Fabien Fillesoye, Fabienne Gourand, Olivier Tirel, Michel Leporrier & Louisa Barré

  2. Université de Caen Basse-Normandie, Caen, France

    Martine Dhilly, Stéphane Guillouet, Delphine patin, Fabien Fillesoye, Ahmed Abbas, Fabienne Gourand, Olivier Tirel, Eric T. MacKenzie, Michel Leporrier & Louisa Barré

  3. CNRS, UMR ISTCT 6301, LDM-TEP Group, GIP Cyceron, Caen, France

    Martine Dhilly, Stéphane Guillouet, Delphine patin, Fabien Fillesoye, Fabienne Gourand, Olivier Tirel, Michel Leporrier & Louisa Barré

  4. CNRS, UMR ISTCT 6301, CERVOxy Group, Caen, France

    Eric T. MacKenzie

  5. INSERM U1077, GIP Cyceron, Bd Henri Becquerel, , BP 5229, , 14074, Caen Cedex, France

    Ahmed Abbas

  6. CHU de Caen, Service d’Anatomie Pathologique, Av. de la Côte de Nacre, , BP 95182, , 14033, Caen Cedex, France

    Françoise Galateau

  7. CRCL, INSERM 1052/CNRS 5286, Hospices Civils de Lyon, University of Lyon, 69008, Lyon, France

    Charles Dumontet

Authors
  1. Martine Dhilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stéphane Guillouet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Delphine patin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fabien Fillesoye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmed Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fabienne Gourand
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Olivier Tirel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Françoise Galateau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eric T. MacKenzie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Charles Dumontet
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michel Leporrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Louisa Barré
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louisa Barré.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhilly, M., Guillouet, S., patin, D. et al. 2-[18F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models. Mol Imaging Biol 16, 118–126 (2014). https://doi.org/10.1007/s11307-013-0659-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-013-0659-2

Key words

Search

Navigation